With $71M investment, French CDMO Yposkesi set to double capacity and become a viral vector force

With demand for viral vectors far exceeding supply, manufacturers are rushing to fill the void. Count French CDMO Yposkesi among them. On Tuesday, the five-year-old company unveiled a plan to build a second commercial cell and gene therapy plant to enhance its ability to produce viral vectors and serve biologic drugmakers. Boosted by investment in… Read More »

Anti-Restenotic Drug Delivery with the AGENT Drug-Coated Balloon: Interview with Dr. Ian Meredith, Global CMO, Boston Scientific

Boston Scientific recently announced a clinical trial of its AGENT drug coated balloon. The device is coated with paclitaxel, an anti-restenotic drug, and aims to deliver the medication to the affected vessel wall during a percutaneous procedure. Coronary in-stent restenosis (ISR) is caused by occlusive scar tissue that develops in the stented portion of a… Read More »